CD82 and acute myeloid leukemia: For this purpose, we employed real-time RT-PCR to compare the levels of EZH2 in CD34+/CD38−/CD82+AML cells and their CD34+/CD38−/CD82− counterparts isolated from AML patients (n = 12; Fig 1E).